Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.36 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327502 | 0.88 | MAP2K4 (0.41) | DYRK1BCLK1DYRK1ADYRK2MAP2K4 | |
| SCHEMBL16143916 | 0.80 | IKBKB (0.41) | DYRK1BCLK1DYRK1ADYRK2KIT | |
| SCHEMBL1702278 | 0.80 | IKBKB (0.40) | DYRK1BCLK1DYRK1ADYRK2KIT | |
| SCHEMBL327582 | 0.78 | HSD17B1 (0.42) | DYRK1BCLK1DYRK1ADYRK2MAP2K4 | |
| SCHEMBL1692467 | 0.77 | MET (0.46) | DYRK1BCLK1DYRK1ADYRK2MAPK10 | |
| SCHEMBL1692212 | 0.76 | CRBN (0.44) | DYRK1BCLK1DYRK1ADYRK2MAP2K4 | |
| SCHEMBL1702956 | 0.76 | KIT (0.41) | DYRK1AMAP2K4KITIKBKBCHUK | |
| SCHEMBL1703190 | 0.74 | CYP3A4 (0.41) | DYRK1BCLK1DYRK1ADYRK2KIT | |
| SCHEMBL12302409 | 0.72 | DYRK1A (0.39) | DYRK1BCLK1DYRK1ADYRK2MAP2K4 | |
| SCHEMBL12302411 | 0.70 | MAPK10 (0.41) | DYRK1BCLK1DYRK1ADYRK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | claimed |
| US-8329712-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | claimed |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2012-01-12 | — | — | US | claimed |
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| WO-2012004212-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RNASE1 | DYRK1B 4859/4885CLK1 3555/4885DYRK1A 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.